These are not hypothetical. They are documented. They are the reason this framework exists — and the reason it believes the legitimate science deserves a better patient protection system.
1
Heartbreak · 2015–2017
Three women went blind in Florida. Each paid $5,000. Each thought it was a clinical trial.
Women aged 72–88 paid $5,000 each for a stem cell procedure at US Stem Cell (then Bioheart) for age-related macular degeneration. Fat cells were liposuctioned from their bellies, processed, and injected directly into both eyes. All three suffered detached retinas, hemorrhages, and severe vision loss. Previously they just had trouble reading small print. Afterward, they could barely see hand movements. The company had listed a "clinical trial" on ClinicalTrials.gov — but the trial had never enrolled anyone. The consent form they signed was for the commercial procedure, not research.
Documented · NEJM · 2017
2
Uplifting · 2023–2025
Justin Graves had a seizure every day. Then he didn't.
Treatment-resistant epilepsy had defined Graves' life. Medications failed. Surgery was ruled out. In a Phase 1 trial at UC San Diego run by Neurona Therapeutics, lab-grown inhibitory neurons were transplanted into his brain — engineered to suppress the electrical misfires triggering his seizures. His seizure frequency dropped from daily to weekly. MIT Technology Review named this work a Top 10 Breakthrough Technology of 2025. Fifteen patients have been treated. The results are early-stage, peer-reviewed, and remarkable.
Neurona Therapeutics · Phase 1 · 2023–2025
3
Heartbreak · 2019
A spinal cord injury patient in Canada received nose cells. A tumor grew instead.
A man who had been paralyzed since a trampoline accident at age 20 underwent a stem cell procedure in Portugal at 26, involving transplantation of cells from inside his nose onto his spinal cord injury site. Instead of relief, he experienced additional pain and no functional improvement. Years later, a mass was found. The case illustrated what University of Minnesota bioethicist Leigh Turner described as the core danger: putting the wrong cells in the wrong location in the human body can produce unwanted effects that aren't clear at the time of treatment.
Documented · CMAJ · 2019
4
Uplifting · 2024
Some type 1 diabetes patients stopped taking insulin entirely.
Vertex Pharmaceuticals reported that some participants in its iPSC-derived pancreatic beta cell trial had completely discontinued insulin injections after treatment. The cells — derived from induced pluripotent stem cells — produce insulin in response to blood sugar changes, restoring a function the patients' own immune systems had destroyed. This is the closest stem cell science has come to a functional cure for type 1 diabetes. The trial is ongoing. The data is peer-reviewed. The manufacturing is documented. This is what legitimate looks like.
Vertex Pharmaceuticals · NEJM · 2024
5
Heartbreak · 2018–2019
A patient died of multiorgan failure after stem cell tourism. No criminal charges followed.
A documented case published in PMC describes a patient who died of multiorgan failure after receiving unproven stem cell treatment abroad. The treatment was administered at a facility with no verifiable GMP status, no identified manufacturer, and no adverse event protocol. The patient had paid tens of thousands of dollars in cash. Due to the cross-border nature of the treatment and the absence of documentation, legal recourse was effectively impossible. No charges were filed in any jurisdiction.
Documented · PMC Case Report · 2019
6
Uplifting · 2023
Sickle cell disease — the disease that has caused suffering for generations — was effectively cured in a clinical trial.
Lyfgenia received FDA approval in December 2023 for sickle cell disease. In clinical trials, 88% of patients achieved complete resolution of vaso-occlusive events between 6 and 18 months post-treatment. This is one treatment, for one indication, with a named manufacturer, a documented COA process, and years of Phase I–III data behind it. It is also expensive — access remains a challenge for most patients. But it is real. It works. It has a paper trail.
Bluebird Bio / FDA Approval · December 2023
7
Heartbreak · 2015–2021
Three Filipino politicians died after stem cell treatments. The investigation was inconclusive.
Philippine news reports documented the deaths of three political figures following stem cell treatments. Investigations were initiated but produced no definitive conclusions about causation. The cases illustrate a consistent pattern: when stem cell adverse events occur — particularly in countries with limited regulatory capacity — the connection between treatment and outcome is almost impossible to establish without documentation that rarely exists.
Philippine Inquirer · 2013
8
Uplifting · 2025
A paralyzed man stood again after receiving reprogrammed stem cells in a Japanese trial.
Nature reported in March 2025 that a paralyzed man regained the ability to stand following treatment with reprogrammed stem cells in a Japanese clinical trial. A second man also regained some movement. Two others showed minimal improvement. The reporting was careful, the trial was rigorous, and the results were honestly characterized — including the patients who did not respond. This is what peer-reviewed, honest stem cell trial reporting looks like. The contrast with commercial clinic marketing is stark.
Nature · March 2025
9
Heartbreak · Ongoing
Patients are charged to participate in "clinical trials" — which is a defining sign of fraud.
Legitimate clinical trials do not charge participants for experimental procedures. This is not a gray area. Yet dozens of for-profit clinics list studies on ClinicalTrials.gov, charge patients $15,000–$50,000 for "trial participation," and use the .gov listing as a legitimacy signal. The NIH has acknowledged the problem. The FDA has issued warnings. But the practice continues. The three women blinded in Florida in 2015 each thought they were participating in a clinical trial. They were not. They were paying customers of a commercial clinic.
Documented Pattern · FDA · NIH
10
Uplifting · 2024
The FDA approved the first MSC therapy. Ever. For children dying of graft-versus-host disease.
Ryoncil (remestemcel-L) received FDA approval in December 2024 as the first mesenchymal stromal cell therapy authorized for any use in the United States. It treats steroid-refractory acute GVHD in pediatric patients — a life-threatening condition that follows allogeneic stem cell transplants. This approval is significant not just for the children it helps but for what it represents: the field can produce approved therapies when evidence, documentation, and endpoints are rigorously established. The standard is achievable. The question is whether the commercial market wants to meet it.
Mesoblast / FDA Approval · December 2024
11
Heartbreak · 2024–2025
The co-founders of Stem Cell Institute of America were banned from marketing — and ordered to pay $5.1M. They had treated thousands of patients.
The FTC action against Stem Cell Institute of America in January 2025 resulted in permanent bans and over $5.1M in refunds and penalties. The company had marketed unproven stem cell treatments for conditions including ALS, Parkinson's, and autism. Thousands of patients had paid for procedures. The bans and penalties came years after the marketing began, years after patients had paid, and years after no documented evidence of efficacy had been produced. The money that was taken from patients vastly exceeded what was returned.
FTC Action · January 2025
12
Uplifting · 2025
Stanford developed a way to do stem cell transplants without toxic chemotherapy conditioning. Three children with Fanconi anemia were cured.
Stanford researchers developed an antibody-based preconditioning method that replaces the chemotherapy and radiation conditioning regimens typically required before stem cell transplants — a change that eliminates some of the most serious side effects of transplant including infertility risk. Three children with Fanconi anemia, a severe genetic blood disorder, were successfully treated and remain healthy two years post-treatment. The finding was described as establishing a safer paradigm for genetic blood conditions and potentially expanding access to transplant therapy for patients who cannot tolerate standard conditioning.
Stanford · Stem Cell Tracker Breakthrough · 2025
13
Heartbreak · Multi-Year
ALS patients have been among the most targeted. None of the treatments marketed to them have evidence of benefit.
ALS — amyotrophic lateral sclerosis — has no cure and no approved stem cell therapy. This has not prevented dozens of clinics from marketing "stem cell therapies" for ALS patients and their families, often at prices of $20,000–$50,000. These patients are among the most desperate and most systematically exploited in the entire regenerative medicine market. R3 Stem Cell was cited by the FDA for marketing unapproved products for ALS. StemGenex was warned for similar practices. Neither resulted in criminal prosecution. Patients continued to be treated and to pay during and after these enforcement actions.
FDA Warning Letters · Ongoing Pattern
14
Uplifting · 2025
Parkinson's disease — untreated by the same approach for 100 years — entered a new era at Memorial Sloan Kettering.
A Phase 1 trial led by Memorial Sloan Kettering Cancer Center transplanted embryonic stem cell-derived dopamine neurons into Parkinson's patients in 2025. Treatments for Parkinson's had relied on substantially the same approach — dopamine replacement — for over a century. Separately, Malin Parmar at Lund University reached the first patient in Swedish clinical trials with an iPSC-derived dopaminergic neuron therapy. Both represent legitimate, rigorously supervised Phase 1 investigations with named researchers, documented protocols, and no patient charge for the experimental procedure.
Memorial Sloan Kettering / Lund University · 2023–2025
15
Heartbreak · 2025
The FDA enforcement chief left CBER. The stem cell market noticed immediately.
In September 2025, under the new HHS leadership of Robert F. Kennedy Jr., a key FDA official at the Center for Biologics Evaluation and Research — the office responsible for oversight of stem cell products — was removed. Within weeks, analysts and patient advocates noted the change. The Supreme Court had just declined (October 2025) to hear the stem cell clinic challenge, theoretically confirming FDA authority. But authority and the will to exercise it are different things. The commercial stem cell market is watching the regulatory environment with the same attention scientists are watching the clinical trial results.
PNAS Report · March 2026
16
Uplifting · 2024
Insulin-producing cells survived transplantation without immunosuppression for the first time.
UCSF Broad Center researchers published results in the New England Journal of Medicine showing that insulin-producing cells can be transplanted without lifelong immune-suppressing drugs — a significant barrier to cell therapy for diabetes. Lifelong immunosuppression creates risks of its own; eliminating the requirement makes curative cell therapy for diabetes substantially more feasible for broader patient populations. The research was conducted in a disclosed academic setting, published in a peer-reviewed journal, and lists the contributing researchers by name.
UCSF Broad Center · NEJM · 2024
17
Heartbreak · Ongoing
Only 13% of stem cell clinics employ physicians trained in the condition they're treating.
A 2019 study of 166 stem cell companies found that only 50% employed a physician at all. Of those who did, only 13% of companies treating non-orthopedic conditions employed physicians with formal training that matched the conditions being treated. A board-certified orthopedic surgeon administering IV stem cells for multiple sclerosis is not operating within the scope of their training. A dermatologist treating ALS with adipose-derived cells is not doing so on the basis of specialty knowledge. These mismatches are routine, rarely disclosed to patients, and almost never acted upon by medical boards.
Pew Charitable Trusts · 2021
18
Uplifting · 2023
CRISPR-edited stem cells cured a genetic blood disease. The world's first CRISPR therapy reached patients.
Casgevy — developed by Vertex and CRISPR Therapeutics — received FDA approval in late 2023 as the first-ever CRISPR-based gene editing therapy for sickle cell disease and transfusion-dependent beta thalassemia. The therapy edits patients' own blood stem cells to induce healthy hemoglobin production. Alliance for Regenerative Medicine CEO Tim Hunt called it "a seminal moment in the history of biotechnology and human health." In 2025, 64 patients received infusions. Access and cost remain significant barriers, but the scientific achievement is unambiguous and real.
Vertex / CRISPR Therapeutics · FDA · December 2023
19
Heartbreak · 2021–2024
A contaminated stem cell product caused a multi-state bloodstream infection outbreak. One recall.
The CDC documented bloodstream infections in patients who received contaminated umbilical-cord-derived injections sold as stem cell therapies, including a multi-state outbreak that prompted a product recall. The infections were caused by contaminated product — a failure of the sterility testing and quality release controls that any legitimate GMP manufacturer would have in place. Patients had paid for these products believing them to be safe. No criminal charges resulted from the contamination incident.
CDC Documentation · Multi-State Outbreak
20
Uplifting · 2025
The Supreme Court confirmed FDA authority over stem cell procedures. After seven years of fighting.
In October 2025, the United States Supreme Court declined to hear the appeal of California stem cell clinics challenging FDA authority to regulate stromal vascular fraction (SVF) procedures. The Ninth Circuit's September 2024 ruling — confirming that same-day SVF treatments do not qualify for the surgical procedure exemption — was left standing. The FDA spent seven years litigating this question. The answer is yes: the FDA can regulate these procedures as drugs. The question for 2026 is whether it will continue to do so with the same force under the current administration.
AABB · SCOTUS · October 2025
21
Heartbreak · Ongoing
Casgevy and Lyfgenia have treated fewer than 200 patients combined — two years after approval. The real patients who need them are still waiting.
Despite FDA approval, broad reimbursement in place, and 100,000 patients in the US with sickle cell disease, only 64 patients received Casgevy infusions in all of 2025, and Lyfgenia has treated just over 100. The conditioning regimen — which involves chemotherapy that causes infertility — is a major barrier. Access in communities most affected by sickle cell disease remains deeply unequal. The therapy that works, for the people who need it most, is available but unreachable. Meanwhile, commercial clinics continue to market unproven interventions to the same populations.
BioSpace · Vertex Earnings · 2026
22
Uplifting · 2025
A new UCSF center is targeting in-utero stem cell therapy for spinal muscular atrophy — before birth.
UCSF Broad Center researchers are demonstrating the promise of in-utero gene therapy for spinal muscular atrophy — a disease that causes progressive muscle weakness and is typically fatal in its most severe form if untreated. The work represents the frontier of stem cell and gene therapy: treating genetic diseases before a patient is born, potentially preventing the disease entirely rather than managing it afterward. This research has named principal investigators, named institutions, peer-reviewed publication, and no patient charge for experimental procedures.
UCSF Broad Center Annual Report · 2024–2025
23
Heartbreak · 2018
The FTC sued a stem cell clinic in 2018 for deceptive advertising. Similar clinics continued operating nearby.
The FTC's 2018 action against Regenerative Medical Group for deceptive health claims established a pattern that has repeated itself consistently: a specific clinic is shut down or penalized, while clinics making substantially similar claims in substantially similar ways continue operating. The enforcement action is clinic-specific. The business model is industry-wide. Every action the FTC and FDA take demonstrates both the seriousness of the problem and the inadequacy of the remedies available to address it at scale.
FTC Action · October 2018
24
Uplifting · 2025
A Phase 1 Parkinson's trial at Memorial Sloan Kettering named its principal researchers, its protocol, and its endpoints. That's rarer than it should be.
The MSK Parkinson's stem cell trial represents something that deserves recognition precisely because it should be the standard: named principal investigators, publicly registered protocol, published Phase 1 design, no patient charge, clearly defined safety endpoints, and a pathway to Phase 2 contingent on Phase 1 results. This is what accountable stem cell research looks like. It is not complicated. It is not expensive relative to what commercial clinics charge. It is simply the result of a research institution caring more about the answer than about the revenue.
Memorial Sloan Kettering · 2025
25
Heartbreak · The Systemic Failure
No one is convicted. No one goes to jail. Patients are injured, blinded, paralyzed, and dead. The market continues.
The most important story in the stem cell market is not a single case. It is the structural reality that the legal system has not produced criminal accountability for any stem cell fraud in the United States despite documented patient blindness, paralysis, infection, and death. The FDA pursues civil injunctions. The FTC extracts civil penalties. Medical boards can revoke licenses. But the underlying business model — charge cash, provide no documentation, make claims that cannot be falsified, operate in a country with limited regulatory capacity, and move on — has not been met with the criminal enforcement that would actually deter it. Until it is, the responsibility for protection sits entirely with the patient.
Systemic Pattern · 2008–2026
